Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme

Medicin og biovidenskab

• temsirolimus 100%
• Bevacizumab 74%
• Glioblastoma 66%
• TOR Serine-Threonine Kinases 16%
• Progression-Free Survival 13%
• Thrombocytopenia 1 12%
• Survival 12%
• Therapeutics 10%
• Tensins 9%
• Temozolomide 9%
• vascular factor 8%
• Proto-Oncogene Proteins c-akt 8%
• Hypertriglyceridemia 8%
• Chemoradiotherapy 7%
• Phosphoric Monoester Hydrolases 7%
• Hypercholesterolemia 7%
• Glioma 6%
• Hyperglycemia 6%
• Vascular Endothelial Growth Factor A 6%
• Phosphotransferases 5%
• Biomarkers 4%
• Hypertension 4%
• Drug Therapy 4%
• Safety 4%
• Recurrence 4%
• Mutation 4%
• Antibodies 4%
• Infections 3%